海辰药业股价跌5.22%，中欧基金旗下1只基金位居十大流通股东，持有93.7万股浮亏损失279.23万元

Group 1 - The core point of the news is that Hainan Pharmaceutical experienced a decline of 5.22% in its stock price, reaching 54.10 CNY per share, with a trading volume of 1.87 billion CNY and a turnover rate of 4.14%, resulting in a total market capitalization of 6.492 billion CNY [1] - Hainan Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, is primarily engaged in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's main business revenue composition includes cardiovascular drugs at 87.12%, antibiotics at 5.69%, active pharmaceutical ingredients and intermediates at 1.68%, digestive drugs at 1.50%, antiviral drugs at 1.47%, and other categories [1] Group 2 - Among the top circulating shareholders of Hainan Pharmaceutical, one fund under China Europe Fund, namely China Europe Enjoy Life Mixed A (010336), entered the top ten shareholders in the third quarter, holding 937,000 shares, which accounts for 1.14% of the circulating shares [2] - The fund, established on January 7, 2021, has a latest scale of 2.004 billion CNY, with a year-to-date return of 12.62%, ranking 5535 out of 8147 in its category, and a one-year return of 5.47%, ranking 6352 out of 8056 [2] - The fund manager of China Europe Enjoy Life Mixed A is Qian Yafeng, who has a cumulative tenure of 10 years and 112 days, with the best fund return during his tenure being 242.9% and the worst being -26.19% [3]